Fintel on MSN3d
Maxim Group Downgrades CNS Pharmaceuticals (CNSP)Fintel reports that on March 25, 2025, Maxim Group downgraded their outlook for CNS Pharmaceuticals (NasdaqCM:CNSP) from Buy ...
The company also continues development of a ... complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin was developed by Dr. Waldemar Priebe ...
Reata Pharma has reported positive clinical ... in chronic kidney disease and diabetic kidney disease. The big pharma company retained an option to license European rights to bardoxolone in ...
Hosted on MSN2mon
BioXcel Therapeutics expands board, appoints new directorAccording to InvestingPro analysis, the company currently operates with ... include Chief Research and Development Officer at Reata Pharmaceuticals (NASDAQ:RETA), as well as executive positions ...
John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...
The company is actively searching for a permanent CEO. Bir brings extensive experience in the pharmaceutical industry, having held leadership roles at Reata Pharmaceuticals (NASDAQ:RETA), Inc ...
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback